Printer Friendly

ROBERTS PHARMACEUTICAL TO ENTER A CLINICAL TRIAL CONTRACT ON NEW DRUG FOR PROSTATE CANCER

 ROBERTS PHARMACEUTICAL TO ENTER A CLINICAL TRIAL CONTRACT ON
 NEW DRUG FOR PROSTATE CANCER
 EATONTOWN, N.J., June 25 /PRNewswire/ -- In a statement made earlier today, Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced that Roberts' contract research organization subsidiary, VRG International, has entered into a contract with Yamanouchi U.K. Limited, a subsidiary of Yamanouchi Pharmaceutical Co., Ltd. of Japan for clinical trials of tamsulosin (YM617), a drug for the treatment of urinary obstruction associated with benign prostatic hypertrophy (BPH). This compound, discovered by Yamanouchi, belongs to a class of compounds known as alpha adrenergic blockers. Tamsulosin is currently entering late stage (Phase III) clinical trials in the United States and awaiting an approval from the Ministry of Health and Welfare in Japan.
 BPH is a common male urological disease affecting about 80 percent of North American men by the time they reach the age of 80. About 10 percent to 20 percent of men over 50 years old will undergo surgery to remove the excess prostate tissue and relieve the blockage. BPH is caused by an overgrowth of prostatic tissue obstructing the urinary bladder outlet. Left untreated, BPH can result in significant urinary tract problems including difficulty in bladder emptying and kidney dysfunction.
 "Tamsulosin is a therapeutic alternative to surgery," said Dr. Robert A. Vukovich, Roberts chairman and CEO. "With tamsulosin, patients with BPH may be able to delay or avoid prostatic surgery entirely."
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and nonprescription pharmaceuticals in the United States and abroad.
 -0- 6/25/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: CON


TQ-OS -- NY058 -- 3886 06/25/92 15:10 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 25, 1992
Words:325
Previous Article:FBS MORTGAGE CORP. CERTIFICATES SERIES 1992-B RATED 'AAA' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:TRANZONIC REPORTS FIRST QUARTER RESULTS
Topics:


Related Articles
ROBERTS PHARMACEUTICAL ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO NEW ANALGESIC DRUG
ROBERTS PHARMACEUTICAL CORPORATION TO ACQUIRE NATIONAL CLINICAL RESEARCH CENTERS
ROBERTS PHARMACEUTICAL RECEIVES IRISH APPROVAL FOR PROSTATE CANCER DRUG
ROBERTS PHARMACEUTICAL REPORTS CLINICAL TRAIL RESULTS FOR NEW ENDOCRINOLOGY DRUG
ROBERTS RECEIVES FDA APPROVAL TO COMMENCE CLINICAL TRIALS WITH DRUG FOR PROSTATE CANCER
/C O R R E C T I O N -- ROBERTS PHARMACEUTICALS/
ROBERTS PHARMACEUTICAL CORPORATION LAUNCHES SUPPRELIN -- ROBERTS' FIRST NEW DRUG LAUNCH IN THE U.S.
CEPHALON AND TAP PHARMACEUTICALS TO DEVELOP DRUGS FOR PROSTATE DISEASE
Novogen Anti-Cancer Drug Enters Phase I Clinical Trials.
OncoGenex Technologies and Isis Pharmaceuticals Achieve Alliance Milestone: Initiate Phase I Clinical Trial of Antisense Drug in Prostate Cancer.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters